

Semiconductors, Ottawa, Ontario, CANADA; OKI Electric Industry Co., Ltd., LSI CAD, Tokyo, JAPAN; OKI Electric Industry Co., Ltd., Telecom, Tokyo, JAPAN; Olympus Optical Co., Ltd., Tokyo, JAPAN; The Open Microprocessor Systems Init, Brussels, BELGIUM; PALMCHIP Corporation, San Jose, CA; Philips Semiconductors, ASIC Design, Sunnyvale, CA; Phoenix Technologies, Ltd., San Jose CA; PrarieComm, Inc., Arlington Heights, IL; Quickturn Design Systems, Inc., Mountain View, CA; ROHM Co., Ltd., Kyoto, JAPAN; Samsung Electronics Co., Ltd., Kyunggi-do, KOREA; SanCraft, Inc., Santa Clara, CA; SAND Microelectronics, Inc., Santa Clara, CA; SANYO Electric Corp., Ltd., Semiconductor, Gunma, JAPAN; Sebring Systems, San Jose, CA; Seiko Epson Corporation, Nagano-ken, JAPAN; SGS Thomson Microelectronics, Bristol, ENGLAND; Sharp Corporation, Nara, JAPAN; SIKAN GmbH, Hannover, GERMANY; Siemens AG, Munich, GERMANY; Sierra Research & Technology, Inc., Westlake Village, CA; Silicon & Software Systems, Dublin, IRELAND; SIS Microelectronics, Inc., Longmont, CO; Smartech Oy, Tampere, FINLAND; Spinnaker Systems, Inc., Tokyo, JAPAN; Summit Design, Inc., Beaverton, OR; Symbios Logic, Inc., Fort Collins, CO; Synchronicity, Inc., Boston, MA; Technical Data Freeway, Inc., Concord, MA; Thine Microsystems, Inc., Tokyo, JAPAN; Texas Instruments, Inc., Semiconductor, Waltham, MA; Tower Semiconductor, Ltd., San Jose, CA; Trimble Navigation Limited, Sunnyvale, CA; Taiwan Semiconductor Manufacturing, Hsin-Chu, TAIWAN; Vantis, Sunnyvale, CA; Victor Co., of Japan, Ltd., Yokohama, JAPAN; Viewlogic Systems, Inc., Rockville, MD; VLSI Technology, Inc., Tempe, AZ; VLSI Libraries, Inc., San Jose, CA; The Western Design Center, Inc., Mesa, AZ; Xilinx, Inc., San Jose, CA; Yokogawa Electric Corporation, Tokyo, JAPAN; and Zycad Corporation, Gatefield Division, Fremont, CA.

No other changes have been made in either the membership or planned activities of VSI. Membership remains open and VSI intends to file additional notifications disclosing all changes in membership.

On November 29, 1996, VSI filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal**

**Register** pursuant to section 6(b) of the Act on March 4, 1997 (62 FR 9812).

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*

[FR Doc. 97-12968 Filed 5-16-97; 8:45 am]

BILLING CODE 4410-11-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated January 27, 1997, and published in the **Federal Register** on February 13, 1997, (62 FR 6802), Isotec, Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Aminorex (1585) .....	I
Methaqualone (2565) .....	I
Lysergic acid diethylamide (7315) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxy-methamphetamine (7405) .....	I
4-Methoxypamphetamine (7411) ..	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
Dihydromorphine (9145) .....	I
Normorphine (9313) .....	I
Acetylmehtadol (9601) .....	I
Alphacetylmethadol Except Levo-Alphacetylmethadol (9603) .....	I
Normethadone (9635) .....	I
3-Methylfentanyl (9813) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
1-Phenylcyclohexylamine (7460) ..	II
Phencyclidine (7471) .....	II
Phenylacetone (8501) .....	II
1-Piperidinocyclohexane-carbonitrile (8603) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Benzoylcegonine (9180) .....	II
Ethylmorphine (9190) .....	II
Hydrocodone (9193) .....	II

Drug	Schedule
Isomethadone (9226) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Methadone intermediate (9254) ..	II
Dextropropoxyphene, bulk (non-dosage forms) (9273) .....	II
Morphine (9300) .....	II
Levo-Alphacetylmethadol (9648) ..	II
Oxymorphone (9652) .....	II
Fentanyl (9801) .....	II

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Isotec, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. § 823 and 28 CFR §§ 0.100 and 0.104, the Acting Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: May 6, 1997.

**Terrance W. Woodworth,**

*Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 97-13078 Filed 5-16-97; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated February 6, 1997, and published in the **Federal Register** on February 21, 1997, (62 FR 8041), Noramco of Delaware, Inc., Division of McNeilab, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Codeine (9050) .....	II
Oxycodone (9143) .....	II
Hydrocodone (9193) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Noramco of Delaware, Inc. to manufacture the listed controlled

substances is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. § 823 and 23 CFR §§ 0.100 and 0.104, the Acting Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: May 6, 1997.

**Terrance W. Woodworth,**

*Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 97-13079 Filed 5-16-97; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Important of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on April 18, 1997, Radian International LLC, 8501 North Mopac Blvd., P.O. Box 201088, Austin, Texas 78720, made application by renewal to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
Ibogaïne (7260) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
4-Bromo-2, 5-dimethoxy-amphetamine (7391) .....	I
4-Bromo-2, 5-dimethoxy-pehenethylamine (7392) .....	I
4-Methyl-2, 5-dimethoxy-amphetamine (7395) .....	I
2, 5-Dimethoxy-amphetamine (7396) .....	I
3, 4-Methylenedioxyamphetamine (7400) .....	I
3, 4-Methylenedioxy-N-ethylamphetamine (7404) .....	I

Drug	Schedule
3, 4-Methylenedioxy-methamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
Etorphine (except HC1) (9056) .....	I
Heroin (9200) .....	I
Pholcodine (9314) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Benzocgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Dextropropoxyphene, bulk (non-dosage forms) (9273) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Levo-alphaacetylmethadol (9648) ..	II
Oxymorphone (9652) .....	II

The firm plans to manufacture small quantities of the listed controlled substances for the manufacture of analytical reference standards.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of these basic classes of controlled substances may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed, in quintuplicate, to the Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than (30 days from publication).

This procedure is to be conducted simultaneously with and independent of the procedure described in 21 CFR 1311.42 (b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic classes of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), (d), (e), and (f) are satisfied.

Dated: May 6, 1997.

**Terrance W. Woodworth,**

*Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 97-13088 Filed 5-16-97; 8:45 am]

BILLING CODE 4410-09-M

## NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: (97-062)]

### Notice of Agency Report Forms Under OMB Review

**SUMMARY:** The National Aeronautics and Space Administration, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. 3506(c)(2)(A)). Reports are required to comply with statutes and implementing regulations.

**DATES:** All comments should be submitted on or before July 18, 1997.

**ADDRESSES:** All comments should be addressed to Mr. Richard Kall, Code HK National Aeronautics and Space Administration, Washington, DC 20546-0001.

**FOR FURTHER INFORMATION CONTACT:** Ms. Carmela Simonson, NASA Reports Officer, (202) 358-1223.

*Title:* Patents.

*OMB Number:* 2700-0048.

*Type of review:* Extension.

*Need and Uses:* The information is needed to ensure the proper disposition of rights to inventions made in the course of NASA funded research.

*Affected Public:* Business or other for-profit, Not-for-profit institutions.

*Number of Respondents:* 7,487.

*Responses Per Respondent:* 1.

*Annual Responses:* 7,487.

*Hours Per Request:* 30 min. to 10 hrs.

*Annual Burden Hours:* 17,870.

*Frequency of Report:* Annually.

**Donald J. Andreotta,**

*Deputy Chief Information Officer (Operations), Office of the Administrator.*

[FR Doc. 97-13045 Filed 5-16-97; 8:45 am]

BILLING CODE 7510-01-M

## NATIONAL SCIENCE FOUNDATION

### Advisory Committee for Social, Behavioral & Economic Sciences; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92-